Literature DB >> 17103436

Blepharophimosis, corneal vascularization, deafness, and acroosteolysis: a "new" syndrome?

Mette Warburg1, Susanne Ullman, Hanne Jensen, Hans Pedersen, Takasi Kobayashi, Bjørn Russell, Lisbeth Tranebjaerg, Gabriele Richard, Karen Brøndum-Nielsen.   

Abstract

We report on a patient with blepharophimosis who after unsuccessful surgery developed progressive corneal vascularization. The patient had conductive hearing loss, acroosteolysis of the phalanges, arthropathy, loss of subcutaneous fat of the hands, feet and face, and oligospermia. He had had spontaneous pneumothorax four times. We have found no similar case reports in the literature and suggest that this is a new syndrome, which must be differentiated from hereditary mucoepithelial dysplasia, mandibuloacral dysplasia, keratitis-ichthyosis-deafness syndrome, Hajdu-Cheney syndrome, Penttinen syndrome, and mucopolysaccharidoses. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 17103436     DOI: 10.1002/ajmg.a.31543

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  3 in total

1.  Recurrent, Activating Variants in the Receptor Tyrosine Kinase DDR2 Cause Warburg-Cinotti Syndrome.

Authors:  Linda Xu; Hanne Jensen; Jennifer J Johnston; Emilio Di Maria; Katja Kloth; Ileana Cristea; Julie C Sapp; Thomas N Darling; Laryssa A Huryn; Lisbeth Tranebjærg; Elisa Cinotti; Christian Kubisch; Eyvind Rødahl; Ove Bruland; Leslie G Biesecker; Gunnar Houge; Cecilie Bredrup
Journal:  Am J Hum Genet       Date:  2018-11-15       Impact factor: 11.025

Review 2.  Lipodystrophy-associated progeroid syndromes.

Authors:  David Araújo-Vilar; Antía Fernández-Pombo; Silvia Cobelo-Gómez; Ana I Castro; Sofía Sánchez-Iglesias
Journal:  Hormones (Athens)       Date:  2022-07-15       Impact factor: 3.419

3.  Progression of skin lesions in Warburg-Cinotti syndrome.

Authors:  Christopher A Ours; Leslie G Biesecker; Thomas N Darling
Journal:  JAAD Case Rep       Date:  2021-12-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.